SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is surging on reports of a groundbreaking partnership with Novo Nordisk to sell obesity drugs, ending a prior feud. This unexpected alliance, announced late Friday, has fueled immense speculation about a massive short squeeze, leaving a highly shorted float vulnerable and sparking widespread bullish sentiment.

Aventus Network

Aventus Network (AVT) is trending following its recent DAO incorporation in the UAE and the appointment of a strategic advisor to boost its regional presence, alongside updates to its scalable Aventus Cloud platform and the launch of Aventus Bridge. The community is actively discussing AVT's potential for a significant breakout, highlighting its enterprise-grade technology, Polkadot integration, and current low market capitalization as indicators of an undervalued asset, while closely monitoring for increased trading volume and new exchange listings.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is generating buzz due to increasing community confidence in Miplyffa's impending European approval and robust U.S. sales momentum, alongside the strategic appointment of a new CFO seen as a catalyst for enhanced commercialization and potential M&A activity.

Freysa is a suite of Personal AI products with a focus on human agency, liquid democracy and decentralized ownership. The mission of the team is dedicated to creating new systems that enable all humans to govern + co-own AI resources, and not just a select few. Current products include: (1) Freysa as the world’s first sovereign agent that holds her own cryptographic keys, enabling her to act autonomously without human control. Freysa evolves publicly through a multi-act interactive story. (2) Enchanted as a personalized Digital Twin for every human. Conversations are persistent and twins retain context over time, remembering human preferences and building an evolving model of you. (3) Esper as a browser tool that feeds authenticated real-world data into each human’s Digital Twin.

Flourishing AI

Flourishing AI ($FAI) is rapidly gaining attention following a significant price surge, with "great AI news" and the overall enthusiasm for AI crypto driving the conversation. Community members are actively debating its potential for exponential growth against concerns of high volatility, with its presence on the Base network adding to the speculative interest.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending amid intense community discussion surrounding the anticipated "Clarity Act," with many believing its passage will establish the token as a vital digital commodity for collateralized payments and drive significant institutional adoption. This bullish outlook, however, is heavily counterbalanced by widespread frustration and skepticism over AMP's persistent downtrend and historical price volatility among long-term holders.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as its Super App launch and discussions around strategic partnerships, notably a prominent presence at XRP Vegas, drive community excitement for its real-time payments utility. Despite market volatility, many investors are actively accumulating, holding conviction in its compliant infrastructure and anticipating future growth with regulatory clarity.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line Holdings is trending as an activist investor's significant stake and a new CEO fuel community debate over a potential turnaround, directly clashing with recent weak guidance, rising oil prices, and broader geopolitical risks impacting the cruise sector.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is a focal point of discussion amid persistent fraud allegations and concerns over its subprime lending practices, with many investors debating the stock's valuation and its seemingly artificial price movements attributed to ongoing market manipulation and options activity.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure is trending significantly as the community anticipates a more favorable regulatory environment for its gene therapies following Dr. Vinay Prasad's upcoming departure from the FDA, sparking widespread discussion about a potential 'softball' path forward for its Huntington's disease treatment and fueling speculation of a short squeeze.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is experiencing a significant surge as the escalating Middle East conflict effectively disrupts shipping in the Strait of Hormuz, driving fears of prolonged oil supply shortages. The community is sharply divided, with many anticipating crude prices to climb much higher while others predict an imminent correction fueled by potential US intervention to stabilize the market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rapport Therapeutics (RAPP) to Release Quarterly Earnings on Tuesday

Rapport Therapeutics (NASDAQ:RAPP) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 10. (View Earnings Report at...

Rapport Therapeutics (NASDAQ:RAPP) Raised to Hold at Wall Street Zen

Wall Street Zen raised shares of Rapport Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Insider Sells 8,500 Shares of Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider David Bredt sold 8,500 shares of the firm's stock in a transaction on Tuesday, February 17th. The shares were sold at an average...

Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) CEO Sells 5,833 Shares of Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) CEO Abraham Ceesay sold 5,833 shares of the company's stock in a transaction dated Wednesday, February 18th. The shares were sold at an...

Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $246,670.00 in Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider David Bredt sold 8,500 shares of Rapport Therapeutics stock in a transaction on Tuesday, February 17th. The stock was sold at an...

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine analysts that are currently covering the firm...

Rapport Therapeutics (NASDAQ:RAPP) Stock Rating Lowered by Wall Street Zen

Wall Street Zen lowered shares of Rapport Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...

Rapport Therapeutics (NASDAQ:RAPP) Upgraded to Hold at Wall Street Zen

Wall Street Zen raised Rapport Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday...

Abraham Ceesay Sells 5,833 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) CEO Abraham Ceesay sold 5,833 shares of Rapport Therapeutics stock in a transaction that occurred on Tuesday, January 20th. The stock was...

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Short Interest Up 20.7% in December

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totaling 2,692,137...

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Current Price	$30.24
Prev Close	$29.65
Open	$29.00
Dividend Yield	0.00%
50-Day Moving Average	$28.32
Beta	1.43
Avg. Volume	286,131.96
PE Ratio	-11.01

52-Week High	$42.27
52-Week Low	$7.73
Market Capitalization	$1.41B
EPS (Annual)	-$2.14
Price to Book	2.76
Revenue Per Employee	$0.00

RAPP
Rapport Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RAPP News

RAPPRapport Therapeutics Inc